Study #2021-1117
ALLG AMLM26 INTERCEPT (Investigating novel therapy to target early relapse and clonal evolution as pre-emptive therapy in AML): A multi-arm, precision-based, recursive, platform trial
MD Anderson Study Status
Enrolling
Treatment Agent
MBG-453 + Azacitidine
Description
To demonstrate the efficacy of targeted and tailored sequential therapy in patients with AML.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
AML
Study phase:
Physician name:
Courtney DiNardo
Department:
Leukemia
For general questions about clinical trials:
1-855-922-5134
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.